{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:20:40Z","timestamp":1761895240963},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s10554-011-9836-z","type":"journal-article","created":{"date-parts":[[2011,2,26]],"date-time":"2011-02-26T10:19:09Z","timestamp":1298715549000},"page":"455-465","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)"],"prefix":"10.1007","volume":"28","author":[{"name":"The APPROACH study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor M.","family":"Garc\u00eda-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Brugaletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Morocutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikheel S.","family":"Kolatkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara G.","family":"Kravitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W.","family":"Nesto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,27]]},"reference":[{"issue":"6","key":"9836_CR1","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ahj.2008.07.025","volume":"156","author":"RE Ratner","year":"2008","unstructured":"Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ (2008) Assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history (approach): Study design and baseline characteristics. Am Heart J 156(6):1074\u20131079. doi: 10.1016\/j.ahj.2008.07.025","journal-title":"Am Heart J"},{"key":"9836_CR2","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garcia-Garcia HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease. The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. doi: 10.1161\/CIRCULATIONAHA.109.881003","DOI":"10.1161\/CIRCULATIONAHA.109.881003"},{"issue":"3","key":"9836_CR3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0735-1097(98)00286-1","volume":"32","author":"A Abizaid","year":"1998","unstructured":"Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB (1998) The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32(3):584\u2013589. doi: S0735-1097(98)00286-1","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"9836_CR4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1161\/01.CIR.0000121358.26097.06","volume":"109","author":"PA Lemos","year":"2004","unstructured":"Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, de Feyter PJ, van Domburg RT, Serruys PW (2004) Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: An evaluation from the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (research) study. Circulation 109(11):1366\u20131370. doi: 10.1161\/01.CIR.0000121358.26097.06","journal-title":"Circulation"},{"key":"9836_CR5","doi-asserted-by":"crossref","unstructured":"Scheen AJ, Warzee F, Legrand VM (2004) Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 25(23):2167\u20132168; author reply 2168\u20132169. doi: 10.1016\/j.ehj.2004.07.041","DOI":"10.1016\/j.ehj.2004.07.041"},{"issue":"19","key":"9836_CR6","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1161\/01.CIR.0000129767.45513.71","volume":"109","author":"I Moussa","year":"2004","unstructured":"Moussa I, Leon MB, Baim DS, O\u2019Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW (2004) Impact of sirolimus-eluting stents on outcome in diabetic patients: A sirius (sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109(19):2273\u20132278. doi: 10.1161\/01.CIR.0000129767.45513.71","journal-title":"Circulation"},{"issue":"6","key":"9836_CR7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcin.2009.04.007","volume":"2","author":"T Takagi","year":"2009","unstructured":"Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, Yoshikawa J (2009) A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: Popps (prevention of in-stent neointimal proliferation by pioglitazone study). JACC Cardiovasc Interv 2(6):524\u2013531. doi: 10.1016\/j.jcin.2009.04.007","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"9836_CR8","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1016\/S0002-8703(03)00547-7","volume":"146","author":"T Takagi","year":"2003","unstructured":"Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J (2003) Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: An intravascular ultrasound scanning study. Am Heart J 146(2):E5. doi: 10.1016\/S0002-8703(03)00146-7","journal-title":"Am Heart J"},{"issue":"11","key":"9836_CR9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.101.11.1311","volume":"101","author":"RE Law","year":"2000","unstructured":"Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA (2000) Expression and function of ppargamma in rat and human vascular smooth muscle cells. Circulation 101(11):1311\u20131318","journal-title":"Circulation"},{"issue":"11","key":"9836_CR10","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2337\/diacare.27.11.2654","volume":"27","author":"D Choi","year":"2004","unstructured":"Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS (2004) Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27(11):2654\u20132660. doi: 27\/11\/2654","journal-title":"Diabetes Care"},{"issue":"2","key":"9836_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.atherosclerosis.2008.05.029","volume":"202","author":"DF Geng","year":"2009","unstructured":"Geng DF, Jin DM, Wu W, Wang Z, Wang JF (2009) Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: A meta-analysis of randomized controlled trials. Atherosclerosis 202(2):521\u2013528. doi: 10.1016\/j.atherosclerosis.2008.05.029","journal-title":"Atherosclerosis"},{"issue":"5","key":"9836_CR12","doi-asserted-by":"crossref","first-page":"762 e761","DOI":"10.1016\/j.ahj.2007.02.022","volume":"153","author":"T Katayama","year":"2007","unstructured":"Katayama T, Ueba H, Tsuboi K, Kubo N, Yasu T, Kuroki M, Saito M, Momomura S, Kawakami M (2007) Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 153(5):762 e761\u2013762 e767. doi: 10.1016\/j.ahj.2007.02.022","journal-title":"Am Heart J"},{"issue":"18","key":"9836_CR13","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1161\/CIRCULATIONAHA.105.535484","volume":"112","author":"N Marx","year":"2005","unstructured":"Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M (2005) Pioglitazone reduces neointima volume after coronary stent implantation: A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112(18):2792\u20132798. doi: 10.1161\/CIRCULATIONAHA.105.535484","journal-title":"Circulation"},{"issue":"5","key":"9836_CR14","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ahj.2003.12.006","volume":"147","author":"A Osman","year":"2004","unstructured":"Osman A, Otero J, Brizolara A, Waxman S, Stouffer G, Fitzgerald P, Uretsky BF (2004) Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 147(5):e23. doi: 10.1016\/j.ahj.2003.12.006","journal-title":"Am Heart J"},{"issue":"1","key":"9836_CR15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2337\/diacare.29.01.06.dc05-1170","volume":"29","author":"K Nishio","year":"2006","unstructured":"Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T (2006) A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 29(1):101\u2013106. doi: 29\/1\/101","journal-title":"Diabetes Care"},{"issue":"2","key":"9836_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.amjcard.2007.02.073","volume":"100","author":"GA Rodriguez-Granillo","year":"2007","unstructured":"Rodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM, de Winter S, Ligthart JM, Deckers JW, Bertrand M, Simoons ML, Ferrari R, Fox KM, Remme W, De Feyter PJ (2007) Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril\u2019s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [perspective] study). Am J Cardiol 100(2):159\u2013163. doi: 10.1016\/j.amjcard.2007.02.073","journal-title":"Am J Cardiol"},{"issue":"1","key":"9836_CR17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ccd.10693","volume":"61","author":"SA Winter De","year":"2004","unstructured":"De Winter SA, Hamers R, Degertekin M, Tanabe K, Lemos PA, Serruys PW, Roelandt JR, Bruining N (2004) Retrospective image-based gating of intracoronary ultrasound images for improved quantitative analysis: The intelligate method. Catheter Cardiovasc Interv 61(1):84\u201394. doi: 10.1002\/ccd.10693","journal-title":"Catheter Cardiovasc Interv"},{"issue":"25","key":"9836_CR18","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1161\/CIRCULATIONAHA.105.558601","volume":"112","author":"J Aoki","year":"2005","unstructured":"Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K, Schiele F, Russell ME, Koglin J, Serruys PW (2005) Peristent remodeling and neointimal suppression 2\u00a0years after polymer-based, paclitaxel-eluting stent implantation: Insights from serial intravascular ultrasound analysis in the taxus ii study. Circulation 112(25):3876\u20133883. doi: 10.1161\/CIRCULATIONAHA.105.558601","journal-title":"Circulation"},{"issue":"9591","key":"9836_CR19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","volume":"370","author":"C Stettler","year":"2007","unstructured":"Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P (2007) Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 370(9591):937\u2013948. doi: 10.1016\/S0140-6736(07)61444-5","journal-title":"Lancet"},{"issue":"14","key":"9836_CR20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa071076","volume":"357","author":"JV Tu","year":"2007","unstructured":"Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R (2007) Effectiveness and safety of drug-eluting stents in ontario. N Engl J Med 357(14):1393\u20131402. doi: 10.1056\/NEJMoa071076","journal-title":"N Engl J Med"},{"issue":"6","key":"9836_CR21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ncpcardio1189","volume":"5","author":"S Windecker","year":"2008","unstructured":"Windecker S, Juni P (2008) Safety of drug-eluting stents. Nat Clin Pract Cardiovasc Med 5(6):316\u2013328. doi: 10.1038\/ncpcardio1189","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"9562","key":"9836_CR22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","volume":"369","author":"J Daemen","year":"2007","unstructured":"Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 369(9562):667\u2013678. doi: 10.1016\/S0140-6736(07)60314-6","journal-title":"Lancet"},{"issue":"Suppl 1","key":"9836_CR23","first-page":"S48","volume":"6","author":"DJ Kereiakes","year":"2005","unstructured":"Kereiakes DJ, Young JJ (2005) Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents. Rev Cardiovasc Med 6(Suppl 1):S48\u2013S58","journal-title":"Rev Cardiovasc Med"},{"issue":"3","key":"9836_CR24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0735-1097(95)00496-3","volume":"27","author":"D Aronson","year":"1996","unstructured":"Aronson D, Bloomgarden Z, Rayfield EJ (1996) Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 27(3):528\u2013535. doi: 0735-1097(95)00496-3","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"9836_CR25","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 287(19):2570\u20132581. doi: jrv10119","journal-title":"JAMA"},{"issue":"1","key":"9836_CR26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jacc.2003.06.019","volume":"43","author":"RA Corpus","year":"2004","unstructured":"Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, Timmis GC, Balasubramaniam M, O\u2019Neill WW (2004) Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type ii diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 43(1):8\u201314. doi: S073510970301324X","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"9836_CR27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-5793(99)00624-9","volume":"452","author":"S Goetze","year":"1999","unstructured":"Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE (1999) Troglitazone inhibits angiotensin ii-induced extracellular signal-regulated kinase 1\/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 452(3):277\u2013282. doi: S0014-5793(99)00624-9","journal-title":"FEBS Lett"},{"issue":"6","key":"9836_CR28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/01.RES.81.6.953","volume":"81","author":"K Yasunari","year":"1997","unstructured":"Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J (1997) Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 81(6):953\u2013962","journal-title":"Circ Res"},{"issue":"4","key":"9836_CR29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/hc3001.092040","volume":"104","author":"Y Aizawa","year":"2001","unstructured":"Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K (2001) Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 104(4):455\u2013460","journal-title":"Circulation"},{"issue":"5","key":"9836_CR30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/01.HYP.0000036396.64769.C2","volume":"40","author":"M Ishibashi","year":"2002","unstructured":"Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A (2002) Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40(5):687\u2013693","journal-title":"Hypertension"},{"issue":"2","key":"9836_CR31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.atherosclerosis.2007.08.030","volume":"197","author":"T Kasai","year":"2008","unstructured":"Kasai T, Miyauchi K, Yokoyama T, Kajimoto K, Sumiyoshi K, Kubota N, Ikeda E, Daida H (2008) Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis 197(2):612\u2013619. doi: 10.1016\/j.atherosclerosis.2007.08.030","journal-title":"Atherosclerosis"},{"issue":"4","key":"9836_CR32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cardiores.2004.11.027","volume":"65","author":"D Li","year":"2005","unstructured":"Li D, Chen K, Sinha N, Zhang X, Wang Y, Sinha AK, Romeo F, Mehta JL (2005) The effects of ppar-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 65(4):907\u2013912. doi: 10.1016\/j.cardiores.2004.11.027","journal-title":"Cardiovasc Res"},{"issue":"3","key":"9836_CR33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0735-1097(00)00799-3","volume":"36","author":"T Takagi","year":"2000","unstructured":"Takagi T, Yoshida K, Akasaka T, Kaji S, Kawamoto T, Honda Y, Yamamuro A, Hozumi T, Morioka S (2000) Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: A serial intravascular ultrasound study. J Am Coll Cardiol 36(3):731\u2013738. doi: S0735-1097(00)00799-3","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"9836_CR34","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457\u20132471. doi: 10.1056\/NEJMoa072761","journal-title":"N Engl J Med"},{"issue":"7","key":"9836_CR35","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","volume":"31","author":"M Komajda","year":"2010","unstructured":"Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD (2010) Heart failure events with rosiglitazone in type 2 diabetes: Data from the record clinical trial. Eur Heart J 31(7):824\u2013831. doi: 10.1093\/eurheartj\/ehp604","journal-title":"Eur Heart J"},{"issue":"2","key":"9836_CR36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijcard.2008.11.048","volume":"131","author":"AJ Coats","year":"2009","unstructured":"Coats AJ (2009) Ethical authorship and publishing. Int J Cardiol 131(2):149\u2013150. doi: 10.1016\/j.ijcard.2008.11.048","journal-title":"Int J Cardiol"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10554-011-9836-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T21:38:42Z","timestamp":1560029922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10554-011-9836-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,27]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["9836"],"URL":"https:\/\/doi.org\/10.1007\/s10554-011-9836-z","relation":{},"ISSN":["1569-5794","1573-0743"],"issn-type":[{"type":"print","value":"1569-5794"},{"type":"electronic","value":"1573-0743"}],"subject":[],"published":{"date-parts":[[2011,2,27]]}}}